Comprehensive medication guide to CellCept including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$57.50–$87.50 copay for generic mycophenolate mofetil (Tier 1–2); brand CellCept copay reduced to as little as $15/month with Genentech co-pay card for commercially insured patients.
Estimated Cash Pricing
$25–$80 with GoodRx or SingleCare coupons for generic mycophenolate mofetil (60 × 500 mg tablets); brand CellCept retails at $886–$1,765 per 60–100 tablets without assistance.
Medfinder Findability Score
55/100
Summarize with AI
On this page
CellCept is the brand name for mycophenolate mofetil (MMF), an immunosuppressant manufactured by Genentech (a Roche company). It is FDA-approved to prevent organ rejection in patients who have received a kidney, heart, or liver transplant, and to prevent graft-versus-host disease after hematopoietic stem cell transplantation. Generic versions of mycophenolate mofetil are available from multiple manufacturers.
CellCept belongs to the class of selective immunosuppressants and works by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), which T and B lymphocytes depend on for proliferation. By selectively blocking these immune cells, CellCept prevents the immune system from attacking a transplanted organ.
Beyond its approved transplant indications, CellCept is widely used off-label for autoimmune diseases including lupus nephritis, vasculitis, myasthenia gravis, and autoimmune hepatitis. It is available as 250 mg capsules, 500 mg tablets, an oral suspension (200 mg/mL), and an IV formulation for hospitalized patients.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
CellCept is a prodrug — meaning it is inactive when you take it and must be converted by the body into its active form. After ingestion, enzymes in the liver, plasma, and other tissues rapidly convert mycophenolate mofetil into mycophenolic acid (MPA), the pharmacologically active molecule.
MPA works by potently, selectively, and reversibly inhibiting inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis pathway for guanosine nucleotides. T and B lymphocytes — the immune cells responsible for organ rejection — depend exclusively on this pathway for DNA replication and cell division. Most other cell types can use an alternative "salvage pathway" that bypasses IMPDH, making CellCept's immunosuppression relatively selective.
By blocking lymphocyte proliferation, CellCept also reduces antibody production, inhibits lymphocyte recruitment to inflammation sites, and suppresses cell-mediated immune responses. Unlike calcineurin inhibitors (tacrolimus, cyclosporine), CellCept is not nephrotoxic at standard doses, making it a valuable partner in kidney transplant regimens.
250 mg — capsule
Brand CellCept: blue-brown two-piece capsule, printed 'CellCept 250' on cap and 'Roche' on body
500 mg — tablet
Brand CellCept: lavender film-coated tablet, printed 'CellCept 500' on one side and 'Roche' on other
200 mg/mL — oral suspension
Liquid form, reconstituted at pharmacy; used primarily for pediatric patients or those unable to swallow tablets
500 mg/vial — IV powder for injection
Hospital use only; administered IV over at least 2 hours
Brand-name CellCept manufactured by Genentech is generally available at specialty pharmacies and mail-order pharmacies. However, generic mycophenolate mofetil — dispensed to most patients — has experienced significant supply disruptions. The American Society of Health-System Pharmacists (ASHP) has documented shortage listings for multiple manufacturers including Hikma, Mylan, Sandoz, Accord, and Ascend, affecting both 250 mg capsules and 500 mg tablets.
The situation is best described as uneven distribution: the medication is being manufactured but not every pharmacy has it at every moment. Patients at chain retail pharmacies are more likely to encounter stock gaps than those using specialty transplant pharmacies or mail order. In 2026, mycophenolate mofetil receives a findability score of 55 out of 100, reflecting intermittent shortages.
If your pharmacy is out of stock, medfinder can help. Enter your medication, dosage, and location, and medfinder calls pharmacies near you to check current availability — then texts you the results.
CellCept is not a controlled substance, so any licensed prescriber can technically write a prescription. However, the FDA recommends that CellCept be prescribed only by physicians experienced in immunosuppressive therapy and management of transplant patients. In practice, the following specialists most commonly prescribe it:
Transplant nephrologists (kidney transplant)
Transplant cardiologists (heart transplant)
Transplant hepatologists (liver transplant)
Transplant surgeons (initial post-operative period)
Rheumatologists (for off-label autoimmune uses: lupus, vasculitis)
Transplant-trained NPs and PAs with specialist oversight
Telehealth is not appropriate for initiating CellCept — the required evaluation, lab workup, and specialist oversight cannot be adequately provided remotely. However, established stable transplant patients may receive follow-up and prescription renewals via telehealth through their transplant center's telemedicine program.
No. CellCept (mycophenolate mofetil) is not a controlled substance and has no DEA scheduling. It has no known abuse potential or diversion risk. Any licensed physician, nurse practitioner, or physician assistant with prescribing authority can prescribe CellCept without any DEA registration or special licensure requirements.
While not controlled, CellCept does carry significant FDA boxed warnings for embryofetal toxicity, malignancies, and serious infections. Only physicians experienced in immunosuppressive therapy and management of transplant patients are recommended to initiate and manage CellCept therapy per the FDA prescribing information. Refills can be called in to any pharmacy without special restrictions.
The most commonly reported side effects of CellCept are gastrointestinal in nature:
Nausea and vomiting
Diarrhea (can be significant)
Stomach pain and cramping
Constipation
Headache, dizziness, and insomnia
Tremors (especially with concurrent tacrolimus)
Rash
Serious infections: Bacterial, viral (CMV, BK virus), and fungal infections including opportunistic infections. Signs: fever, chills, cough, shortness of breath.
Progressive multifocal leukoencephalopathy (PML): Rare but potentially fatal brain infection. Symptoms: confusion, speech changes, vision changes, weakness.
Blood disorders: Neutropenia, thrombocytopenia, anemia, pure red cell aplasia.
Malignancies: Lymphoma, skin cancer. Annual skin cancer screening is recommended.
Embryofetal toxicity: High risk of miscarriage and severe birth defects if taken during pregnancy. Two forms of contraception required during treatment.
Know what you need? Skip the search.
Myfortic (mycophenolate sodium)
Delayed-release form of mycophenolate; same active drug delivered as a different salt; may cause less GI upset; NOT directly interchangeable without dose adjustment
Tacrolimus (Prograf)
Calcineurin inhibitor used alongside CellCept in most transplant protocols; different mechanism (IL-2 blockade vs. IMPDH inhibition)
Azathioprine (Imuran)
Older antimetabolite; used as antiproliferative alternative in some protocols, especially in tacrolimus-based regimens; 6-10x cheaper than MMF
Sirolimus (Rapamune)
mTOR inhibitor; alternative antiproliferative for kidney transplant patients; not used in liver transplant due to hepatic artery thrombosis risk
Prefer CellCept? We can find it.
Cyclosporine (Neoral/Sandimmune)
majorInhibits enterohepatic recirculation of MPA, reducing CellCept levels by 30–40%; dose adjustments needed when switching between cyclosporine and tacrolimus-based regimens
Cholestyramine
majorBinds MPA in the gut, substantially reducing reabsorption and effective drug levels; avoid combination if possible
Proton pump inhibitors (omeprazole, esomeprazole, lansoprazole)
moderateIncrease gastric pH, reducing MMF absorption by approximately 25–35%; clinically relevant interaction for transplant patients
Antacids (aluminum/magnesium hydroxide)
moderateReduce MMF absorption; separate administration by at least 2 hours
Acyclovir/Ganciclovir/Valganciclovir
moderateCompete with MPA for renal tubular secretion; increases levels of both drugs, raising bone marrow suppression risk especially with renal impairment
Oral contraceptives
moderateCellCept reduces hormonal contraceptive effectiveness; a second non-hormonal contraceptive method is required simultaneously
Live vaccines
majorContraindicated during CellCept therapy; live vaccines may cause serious infection in immunosuppressed patients and may not be effective
Metronidazole/Norfloxacin
moderateMay reduce MPA levels by disrupting gut bacteria involved in enterohepatic recirculation
CellCept (mycophenolate mofetil) is one of the most important medications in modern transplant medicine. For kidney, heart, and liver transplant recipients, it is a lifelong medication that is central to keeping the transplanted organ functioning. Its selective mechanism of action — targeting T and B lymphocytes through IMPDH inhibition — makes it a foundational immunosuppressant in virtually all solid organ transplant protocols.
In 2026, CellCept availability requires some planning. Generic mycophenolate mofetil supply is uneven across pharmacies, with several major manufacturers having experienced shortage periods. Brand CellCept remains generally available, particularly at specialty pharmacies. For transplant patients, proactive refill management — early refills, 90-day supplies, and specialty pharmacy relationships — is essential to avoid dangerous supply gaps.
If you're having trouble finding CellCept in stock, medfinder can help locate it at pharmacies near you. Enter your medication, strength, and location, and medfinder calls pharmacies on your behalf and texts you results — covering all medications and all pharmacy types.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini